Sugi Predict

Sugi Predict / Targets / SRD5A2

SRD5A2

3-oxo-5-alpha-steroid 4-dehydrogenase 2 · P31213 · SRD5A2 on Sugi Atlas →

103,610 patent compounds predicted against SRD5A2, 73,730 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Epristeride Epristeride (SCHEMBL61222) 1.00 15/20
SCHEMBL69729 SCHEMBL69729 1.00 10/20
Finasteride Finasteride (SCHEMBL5509) 1.00 9/20
Finasteride Finasteride (SCHEMBL11909) 1.00 9/20
Dutasteride Dutasteride (SCHEMBL5903) 1.00 8/20
SCHEMBL110317 SCHEMBL110317 0.74 8/20
SCHEMBL109656 SCHEMBL109656 0.57 8/20
SCHEMBL110606 SCHEMBL110606 0.50 8/20
Turosteride Turosteride (SCHEMBL62002) 1.00 7/20
SCHEMBL81964 SCHEMBL81964 1.00 7/20
SCHEMBL80558 SCHEMBL80558 0.49 6/20
SCHEMBL38133 SCHEMBL38133 0.48 6/20
SCHEMBL105660 SCHEMBL105660 0.46 6/20
SCHEMBL78879 SCHEMBL78879 0.87 5/20
SCHEMBL27506 SCHEMBL27506 0.81 5/20
SCHEMBL124917 SCHEMBL124917 0.80 5/20
SCHEMBL22281 SCHEMBL22281 0.75 5/20
SCHEMBL21786 SCHEMBL21786 0.62 5/20
SCHEMBL94869 SCHEMBL94869 0.60 5/20
SCHEMBL83789 SCHEMBL83789 0.56 5/20

Clinical trials — most relevant to SRD5A2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment PHASE4RECRUITING
The Role of 5-alpha Reductase in Mediating Testosterone Actions PHASE4COMPLETED
The Effect of 5-Alpha Reductase on Testosterone in Men PHASE3UNKNOWN
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents PHASE3WITHDRAWN
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia PHASE2RECRUITING
Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3] PHASE1/PHASE2COMPLETED
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA) PHASE2COMPLETED
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency PHASE1COMPLETED
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers nanUNKNOWN
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas nanUNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Final Height in Patients With CAH nanUNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency nanCOMPLETED
Gene Polymorphisms Influencing Steroid Synthesis and Action nanWITHDRAWN
Androgen Metabolism and Reproductive Outcome nanCOMPLETED
Early Mental Response - The EMRE Study nanRECRUITING
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study nanCOMPLETED
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome nanCOMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH nanCOMPLETED
FEmale Metabolic Risk and Androgens: an Irish Longitudinal (FEMAIL) Study nanRECRUITING
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes nanNOT_YET_RECRUITING
Study of Adrenal Gland Tumors nanCOMPLETED
Androgenetic Alopecia and the JAK-STAT Pathway nanCOMPLETED
Effects and Interactions of Liquorice and Grapefruit on Glucocorticoid Replacement Therapy in Addison's Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SRD5A2 binder may also engage these)

ProteinNameSimilarity
Q28892 — 1.000 Q28892 →
P31214 — 1.000 P31214 →
O18765 — 0.999 O18765 →
Q99N99 — 0.996 Q99N99 →
P24008 — 0.988 P24008 →
Q5K2N1 — 0.983 Q5K2N1 →
Q38944 — 0.983 Q38944 →
Q68FF9 — 0.979 Q68FF9 →
Q28891 — 0.976 Q28891 →
Q5RIU9 — 0.975 Q5RIU9 →
Q9WVM4 — 0.975 Q9WVM4 →
Q9EQK7 — 0.973 Q9EQK7 →
SRD5A1 3-oxo-5-alpha-steroid 4-dehydrogenase 1 0.972 landscape →
A8X8R3 — 0.972 A8X8R3 →
O12947 — 0.971 O12947 →
Q9CAH5 — 0.971 Q9CAH5 →
ICMT Protein-S-isoprenylcysteine O-methyltransferase 0.971 landscape →
Q2QDF6 — 0.971 Q2QDF6 →
Q55C17 — 0.970 Q55C17 →
A5PJS2 — 0.969 A5PJS2 →
Q9N5Y2 — 0.968 Q9N5Y2 →
Q5R7H4 — 0.968 Q5R7H4 →
Q17428 — 0.967 Q17428 →
Q8VD00 — 0.967 Q8VD00 →
O08984 — 0.967 O08984 →
Q71KT5 — 0.966 Q71KT5 →
Q9SI62 — 0.966 Q9SI62 →
Q9UT20 — 0.966 Q9UT20 →
Q9VLP9 — 0.965 Q9VLP9 →
Q3U9G9 — 0.965 Q3U9G9 →